SQS Software Quality Systems AG

  • WKN: 549351
  • ISIN: DE0005493514
  • Land: Deutschland

Nachricht vom 20.03.2017 | 19:00

DGAP-DD: SQS Software Quality Systems AG english


SQS Software Quality Systems AG: Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

20.03.2017 / 19:00
The issuer is solely responsible for the content of this announcement.


20 March 2017

SQS Software Quality Systems AG
('SQS', the 'Company' or the 'Group')

Director / PDMR shareholdings

The Company announces that it received notification from David Bellin, Chairman of its Supervisory Board, on 15 March 2017 that, on the same date, his wife Mrs E A Bellin purchased at a price of 505 pence per SQS Share 2,000 shares.

As a result of this transaction, the number of Ordinary Shares which Mr. Bellin owns or is directly interested in has increased from 5,600 Ordinary Shares to 7,600 Ordinary shares, representing 0.02% of the issued share capital of the Company.

The Company announces that it received notification from Diederik Vos, CEO, on 15 March 2017 that, on the same date, he purchased at a price of 505 pence per SQS Share 2,000 shares.

As a result of this transaction, the number of Ordinary Shares which Mr. Vos owns or is directly interested in has increased from 1,000 Ordinary Shares to 3,000 Ordinary shares, representing 0.01% of the issued share capital of the Company.

Ends

Enquiries:

SQS Software Quality Systems AG Tel. +49 (0) 2203 91 54 0
Diederik Vos, Chief Executive Officer  
Rene Gawron, Chief Financial Officer  
Numis Securities - Nomad and Joint Broker Tel +44 (0) 20 7260 1000
Simon Willis / Jamie Lillywhite / Mark Lander  
   
Stockdale Securities - Joint Broker Tel. +44 (0) 20 7601 6100
Robert Finlay / Antonio Bossi  
FTI Consulting - Financial Media and Investor Relations Tel. +44 (0)20 3727 1000
Matt Dixon / Dwight Burden sqs@fticonsulting.com
 

About SQS

SQS is the leading global specialist in end-to-end software and business process quality solutions. This position stems from over 30 years of successful consultancy operations. SQS consultants provide solutions for all aspects of quality throughout the whole software product lifecycle driven by a standardised methodology, offshore automation processes and deep domain knowledge in various industries. Headquartered in Cologne, Germany, the company now employs approximately 4,600 staff. SQS has offices in Germany, UK, US, Australia, Austria, Egypt, Finland, France, India, Ireland, Italy, Malaysia, the Netherlands, Norway, Singapore, South Africa, Sweden, Switzerland and UAE. In addition, SQS maintains a minority stake in a company in Portugal. In 2016, SQS generated revenues of EUR327.1 million.

SQS is the first German company to have a primary listing on AIM, a market operated by the London Stock Exchange. In addition, SQS shares are also traded on the German Stock Exchange in Frankfurt am Main.

With over 10,000 completed projects under its belt, SQS has a strong client base, including half of the DAX 30, nearly a third of the STOXX 50 and 20 per cent of the FTSE 100 companies.

For more information, see www.sqs.com

SQS Software Quality Systems AG

DEALING NOTIFICATION FORM
FOR USE BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITY AND THEIR CLOSELY ASSOCIATED PERSONS

  Details of the person discharging managerial responsibilities/person closely associated
a) Name:

Elizabeth Bellin
  Reason for the notification
a) Position/status:

Wife of the Chairman of the Supervisory Board
b) Initial notification/Amendment:

Initial
  Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a) Name: SQS Software Quality Systems AG
b) LEI: 529900DU5PBUHKEESW60
  Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a) Description of the financial instrument, type of instrument: Ordinary shares of EUR1 each.

Identification code: ISIN DE0005493514
b) Nature of the transaction:

Purchase
c) Price(s) and volume(s):

Price(s)
505p

Volume(s)
10,100 GBP
d) Aggregated information:

Aggregated volume: 10,100 GBP

Price: 505p
e) Date of the transaction: 15/03/2017
f) Place of the transaction: XLON
 
1. Details of the person discharging managerial responsibilities/person closely associated
a) Name:

Diederik Vos
2. Reason for the notification
a) Position/status:

CEO
b) Initial notification/Amendment:

Initial
3. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a) Name: SQS Software Quality Systems AG
b) LEI: 529900DU5PBUHKEESW60
4. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a) Description of the financial instrument, type of instrument: Ordinary shares of EUR1 each.

Identification code: ISIN DE0005493514
b) Nature of the transaction:

Purchase
c) Price(s) and volume(s):

Price(s)
505p

Volume(s)
10,100 GBP
d) Aggregated information:

Aggregated volume: 10,100 GBP

Price: 505p
e) Date of the transaction: 15/03/2017
f) Place of the transaction: XLON


20.03.2017 The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de



show this

Anleihe im Fokus

EYEMAXX Real Estate AG: EYEMAXX begibt Wandelanleihe im Volumen von bis zu 20,376 Mio. Euro

Kupon:4,5%

Bezugsfrist: bis 12. April 2017 (12.00 Uhr)

Öffentliches Angebot:bis 18. April 2017 (12.00 Uhr)

Laufzeit:bis einschließlich 15. Dezember 2019

ISIN: DE000A2DAJB7

GBC im Fokus

Neovacs S.A.: Kursziel auf 3,30 € angehoben

In den letzten Monaten hatte die Neovacs S.A. einen positiven Newsflow. Im Vordergrund steht die Vertriebspartnerschaft für den chinesischen Markt, wodurch sich bis nach dem ersten Vermarktungsjahr Gesamterträge von bis zu 65 Mio. € ergeben können. Zudem verläuft der klinische Zulassungsprozess des IFNα-Kinoid zur Behandlung von SLE (Systemischer Lupus) und Dermatomyositis planmäßig. Wir haben in unsere Bewertung aktualisiert und ein Kursziel von 3,30 € je Aktie (bisher: 2,90 €) ermittelt. Das Rating lautet weiter KAUFEN.

Event im Fokus

65. m:access Analystenkonferenz

Datum: 06.04.2017
Zeit: 09:30 - 17:00 Uhr
Ort: Börse München
Karolinenplatz 6
80333 München

News im Fokus

Vonovia SE: 93,09 % der conwert-Aktionäre nehmen das Übernahmeangebot von Vonovia an

27. März 2017, 18:18

Aktueller Webcast

Scout24 AG

Full Year Results 2016

29. März 2017

Aktuelle Research-Studie

Ergomed plc

Original-Research: Ergomed plc (von GBC AG): Kaufen

29. März 2017